This announcement is a separate document:
Clarity Pharmaceuticals Ltd: First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.